Study if the Presence of Functional FcERI/RII on the Surface of Human Blood Platelet

NCT05848986 | Unknown

• 1 other identifier: 8947
• Study Type: observational
• Target: 20
• Locations: 1 country
• Sites: 1

Brief Summary

Anaphylactic shock is the most severe expression of immediate hypersensitivity reactions. The mechanisms leading to these reactions are still poorly understood and may involve platelets, especially in the most severe forms. The IgE ( ImmunoglobulineE)-mediated mechanism, involving the FcERI(the high-affinity receptor for the Fc region of immunoglobulin E (IgE) receptor present on the surface of mast cells and basophilic cells, is the most common mechanism. The receptors FcERI and FcERII are also described as being present on the surface of blood platelets, which would imply their activation along with the other cells involved. However, studies showing the presence of the FcERI/RII receptors on blood platelets suffer from many biases. The main objective of the research is to study whether the FcERI/RII receptors are present and functional on the surface of blood platelets from allergic patients.

Conditions

Allergy

Outcome Measures

Primary Outcomes (1)

• Presence of functionnal FcERI/RII receptors on the surface of blood platelets from allergic patients

  After confirmation of the allergy by a well conducted allergy workup

  1 day

Interventions

Flow cytometry OTHER

Analysis of blood samples from a health sample's allergic patients and analysis with flow cytometry

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients assessed in the allergy clinic of the Strasbourg University Hospital

You may qualify if:

• Age \> 18 years-old
• With a protein/drug allergy (hymenoptera, arachide, amoxicillin)
• Confirmed by skin tests and/or challenge test
• With specific IgEs

You may not qualify if:

• Patients who refuse to participate to this study
• Patients unable to consent

Sponsors & Collaborators

• University Hospital, Strasbourg, France: lead

Study Sites (1)

Les Hôpitaux Universitaires

Strasbourg, 67091, France

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

Whole blood, platelet rich plasma Obtained from a constituted biocollection.

MeSH Terms

Conditions

Hypersensitivity

Interventions

Flow Cytometry

Condition Hierarchy (Ancestors)

Immune System Diseases

Intervention Hierarchy (Ancestors)

Cell Separation; Cytological Techniques; Clinical Laboratory Techniques; Diagnostic Techniques and Procedures; Diagnosis; Cytophotometry; Fluorometry; Luminescent Measurements; Photometry; Chemistry Techniques, Analytical; Investigative Techniques

Study Officials

• CHARLES AMBROISE TACQUARD, MD

  University Hospital, Strasbourg, France

  PRINCIPAL INVESTIGATOR

Central Study Contacts

CHARLES AMBROISE TACQUARD, MD

CONTACT

03 69 55 16 08; charlesambroise.tacquard@chru-strasbourg.fr

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: OTHER
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 27, 2023
• First Posted: May 8, 2023
• Study Start: June 1, 2023
• Primary Completion: June 1, 2023
• Study Completion: April 1, 2025
• Last Updated: May 8, 2023

Record last verified: 2023-03

Data Sharing

• IPD Sharing: Will not share

Locations

FR (1)